Market Place
Sourcing Support
Quince Therapeutics Business & Reports Q3 2024 Financial Results
13 Nov 2024 //
BUSINESSWIRE
Quince Therapeutics Presents ATTeST Data at Ataxia Congress
12 Nov 2024 //
BUSINESSWIRE
Quince Presents ATTeST Phase 3 Safety Data at CNS Meeting
11 Nov 2024 //
BUSINESSWIRE
Quince Therapeutics to Participate at Upcoming Investor Conferences
14 Oct 2024 //
BUSINESSWIRE
Quince Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
BUSINESSWIRE
Quince Announces Lancet Neurology Publication Of Phase 3 EryDex Trial Data
15 Aug 2024 //
BUSINESSWIRE
Quince Therapeutics Reports Q2 2024 Results And Business Update
13 Aug 2024 //
BUSINESSWIRE
Quince doses first patient in Phase 3 trial of EryDex for Ataxia-Telangiectasia
25 Jun 2024 //
BUSINESSWIRE
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex
04 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
03 Jun 2024 //
BUSINESSWIRE
Quince Therapeutics Provides Update, Reports Q1 2024 Results
13 May 2024 //
BUSINESSWIRE
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
06 May 2024 //
BUSINESSWIRE
Quince Provides Business Update and Reports Q4 and Fiscal 2023 FR
01 Apr 2024 //
BUSINESSWIRE
Quince Therapeutics Launches Scientific Advisory Board
22 Feb 2024 //
BUSINESSWIRE
Quince Therapeutics Appoints Dr. Rajiv Patni to its Board of Directors
15 Feb 2024 //
BUSINESSWIRE
Quince to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 Feb 2024 //
BUSINESSWIRE
Quince Therapeutics to Participate at Investor Events in January 2024
04 Jan 2024 //
BUSINESSWIRE
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
23 Oct 2023 //
BUSINESSWIRE
Quince eyes PhIII start for rare pediatric disease drug-device as FDA lifts hold
29 Sep 2023 //
ENDPTS
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
06 Sep 2023 //
BUSINESSWIRE
Quince to Present at Sidoti Virtual Investor Conference on August 17, 2023
10 Aug 2023 //
BUSINESSWIRE
Quince buys a rare disease biotech
24 Jul 2023 //
ENDPTS
Quince Therapeutics board gives flat-out rejection to unsolicited buyer
11 Apr 2023 //
ENDPTS
Quince Board of Directors Unanimously Rejects Unsolicited Proposal
11 Apr 2023 //
BUSINESSWIRE
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor
06 Apr 2023 //
BUSINESSWIRE
Quince adopts `poison pill` to fend off buyout, stock purchases
06 Apr 2023 //
FIERCE BIOTECH
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
05 Apr 2023 //
BUSINESSWIRE
Quince Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
22 Mar 2023 //
BUSINESSWIRE
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
30 Jan 2023 //
BUSINESSWIRE
Quince to lay off nearly half of team, sell more assets
30 Jan 2023 //
FIERCE BIOTECH
Quince`s former leaders return for unwanted Alzheimer`s assets
27 Jan 2023 //
FIERCE BIOTECH
Quince Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse
27 Jan 2023 //
BUSINESSWIRE
Quince Presents Data Demonstrating Efficacy of Bone-targeting Platform
16 Sep 2022 //
BUSINESSWIRE
Quince Presents Data Demonstrating Application of Bone-targeting Platform
12 Sep 2022 //
BUSINESSWIRE
Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential
30 Aug 2022 //
BUSINESSWIRE
Quince Therapeutics to Present at Upcoming Scientific Meetings
25 Aug 2022 //
BUSINESSWIRE
Quince Therapeutics to Present at Canaccord Genuity Conference on August 11
04 Aug 2022 //
BUSINESSWIRE
Quince hoping to sweeten its fruit with new strategic plan
01 Aug 2022 //
FIERCEBIOTECH
Cortexyme Completes PI Single and Multiple Ascending Dose Trial of COR588
27 Jul 2022 //
BUSINESSWIRE
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on Aug 1
27 Jul 2022 //
BUSINESSWIRE
Cortexyme Announces PC Data on Efficacy of COR803 for Coronavirus Infections
21 Jun 2022 //
BUSINESSWIRE
Cortexyme Appoints June Bray to its Board of Directors
13 Jun 2022 //
BUSINESSWIRE
Cortexyme Successfully Completes Acquisition of Novosteo
20 May 2022 //
BUSINESSWIRE
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
20 May 2022 //
BUSINESSWIRE
Cortexyme to Participate at 4th International Conference on P. gingivalis
12 May 2022 //
BUSINESSWIRE
Cortexyme Charts New Course With Acquisition Of Rare Disease Player
11 May 2022 //
PHARMALIVE
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 on Lysine Gingipain
21 Mar 2022 //
BUSINESSWIRE
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
15 Mar 2022 //
BUSINESSWIRE
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
14 Mar 2022 //
BUSINESSWIRE
Cortexyme Announces Preclinical Data Showing Benefits of Atuzaginstat
09 Mar 2022 //
BUSINESSWIRE
Cortexyme Reports Safety, Pharmacokinetics Results from Phase 1 Trial of COR588
08 Mar 2022 //
BUSINESSWIRE
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
01 Feb 2022 //
BUSINESSWIRE
Cortexyme to focus on 2nd Alzheimer`s bet after clinical hold
27 Jan 2022 //
FIERCEBIOTECH
Cortexyme picks a lower dose for nebulous Alzheimer`s drug
13 Nov 2021 //
BIOPHARMADIVE
Atuzaginstat Slowed Cognitive Decline in Alzheimer’s & P. Gingivalis Infection
11 Nov 2021 //
BUSINESSWIRE
Keystone Bio Recognizes the Big "GAIN" from Cortexyme`s Trial Results
09 Nov 2021 //
BUSINESSWIRE
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis
04 Nov 2021 //
BUSINESSWIRE
Cortexyme will forge ahead with failed Alzheimer`s drug
27 Oct 2021 //
STATNEWS
Cortexyme gets dosing underway in early-stage COR588 trial
08 Sep 2021 //
SEEKING ALPHA
Cortexyme Expands Pipeline with Initiation of Phase 1 Trial of COR588
08 Sep 2021 //
BUSINESSWIRE
